NeoGenomics (NEO) – Analyst Ratings
-
Healthcare a contrarian idea into 2024 - these stocks could see upside
-
Stephens Upgrades Neogenomics (NEO) to Overweight
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
Back to NEO Stock Lookup